Skip to main content
. Author manuscript; available in PMC: 2015 Feb 11.
Published in final edited form as: Cancer. 2010 Oct 19;117(5):982–991. doi: 10.1002/cncr.25533

Table 1.

Baseline Characteristics of Patients

Clinical Feature Median [Range] or No. (%) P
No ESA, n = 391 ESA, n = 217
Age, y 49 [15–81] 57 [17–84] <.0001
Male sex 258 (66) 94 (43) <.0001
Stage .92
ECP 198 (51) 109 (50)
LCP 193 (49) 108 (50)
Spleen size, cm from left costal margin 0 [0–20] 0 [0–25] .32
WBC, ×109/L 14.5 [1.6–283] 18 [1.8–239] .14
Hb, g/dL 12.9 [7.9–16.9] 11.7 [6.2–14.6] <.0001
Platelets, ×109/L 288 [58–1476] 334 [82–1324] .09
PB blasts 0 [0–12] 0 [0–12] .08
BM blasts 1 [0–14] 1 [0–14] .10
Sokal risk score <.0001
Low 299 (76) 124 (57)
Intermediate 77 (20) 75 (35)
High 15 (4) 18 (8)
Previous IFN-α 194 (50) 108 (50) .97
Ph1+ at start of imatinib >90% 320 (82) 189 (88) .10
Time from diagnosis to imatinib, mo 8 [0–218] 6.5 [0–194] .61
High dose imatinib, % 155 (40) 94 (43) .37

ESA indicates erythropoietic-stimulating agent; ECP, early chronic phase; LCP, late chronic phase; WBC, white blood cell count; Hb, hemoglobin; PB, peripheral blood; BM, bone marrow; IFN, interferon; Ph1+, Philadelphia chromosome positive.